The COOPerative Establishment for Necessary Investigation in Clinical Outcome After Stenting (COPERNICOS)
Randomized Comparison of Outcome of Stenting in Unselected Patients in Everyday Clinical Practice
The superiority of a percutaneous coronary intervention (PCI) by one stent over another in terms of clinical outcome is usually documented in large randomized controlled trials (RCT). Although generated from selected study populations these data form the basis for evidence based practice (EBP) in the entire population of patients considered for coronary intervention. An inherent limitation of this approach is that study populations differ significantly from all comers in terms of patient characteristics and prognosis undermining the foundation for extrapolation of trial results to all comers. Furthermore, other trials are based on a "one-fits-all" concept, while the benefits of an "individual-tailored" approach that might be superior, is not investigated.
The Purpose of the current study is to
- Compare clinical outcome between several CE marked drug eluting stents
- Compare clinical outcome between several CE marked bare metal stents
- Compare clinical outcome in all comers with that of the selected study population of RCT's
- Evolve methods to compare clinical outcomes between the generalized "one-fits-all" versus the individualized or "individual-tailored" stent selection approaches
The Method employed is
- All comer PCI registry - single centre
- Randomisation of all eligible patients within the registry to one of several study stent
- Quality assurance in non-randomized population within the registry by periodical alternating the institutional standard stent
- Continuous follow up of all patients included the registry by means of systematic event detection and classification by an independent safety and end point committee
- Assessment of effects on quality of life by heart and health questionnaires
Outcome Measures
Primary endpoints:
- Composite of cardiac death, acute myocardial infraction and target vessel revascularisation
- Stent thrombosis
- A specifically developed Treatment Failure Rate classification
Secondary outcome measures include each of the above, target lesion revascularisation and total death analyzed in a hierarchical fashion at 2, 3, 4 and 5 years.
Tertiary outcome measure is self reported quality of life based on health questionnaires on general health and cardiac symptoms.
Power Calculations An event rate of 20% within 5 years, a relative difference of 25% (an absolute difference of 5%), P< 5%, Power > 80% => 900 patients in each of two treatment arms.
Prespecified Analysis include
- The MACE rates between stent types
- The Stent thrombosis rates between stent types
- The Treatment failure rates between stent types
- The randomized population versus non-randomized population
- The individualized versus the generalized Population
- QOL between stent types
Tutkimuksen yleiskatsaus
Tila
Ehdot
Interventio / Hoito
Yksityiskohtainen kuvaus
All MACE and stent thromboses are adjudicated by an independent end point and safety committee chaired by Jørgen Jeppesen known from the very same task he executed in the SORT OUT II.
Further question may be answered by the four key investigators:
Steen Carstensen, Anders Galløe, Ole Havndrup, Lars Kjøller-Hansen
Opintotyyppi
Ilmoittautuminen (Odotettu)
Vaihe
- Vaihe 4
Yhteystiedot ja paikat
Opiskelupaikat
-
-
-
Roskilde, Tanska, 4000
- Roskilde County Hospital
-
-
Osallistumiskriteerit
Kelpoisuusvaatimukset
Opintokelpoiset iät
Hyväksyy terveitä vapaaehtoisia
Sukupuolet, jotka voivat opiskella
Kuvaus
Inclusion Criteria:
- to enter COPERNICOS registry for quality assessment: Each and every patient assigned to percutaneous coronary intervention will be included.
- to enter COPERNICOS randomization: If the patient fulfil the Helsinki declaration and have a Danish personal security identification number they are asked to give written informed consent to participate in the randomized study arms.
Exclusion Criteria to randomization:
- unconscious patients
- residents in other countries thereby escaping event detection
- patients unable to understand the rationale of the study.
Opintosuunnitelma
Miten tutkimus on suunniteltu?
Suunnittelun yksityiskohdat
- Ensisijainen käyttötarkoitus: Hoito
- Jako: Satunnaistettu
- Inventiomalli: Rinnakkaistehtävä
- Naamiointi: Yksittäinen
Aseet ja interventiot
Osallistujaryhmä / Arm |
Interventio / Hoito |
|---|---|
|
Active Comparator: Study group two
Endeavor resolute drug eluting stent
|
Biomatrix drug eluting stent
Muut nimet:
|
|
Active Comparator: Study group three
The precise selection of brand name depends on negotiations with suppliers and may change during the study period
|
Biomatrix drug eluting stent
Muut nimet:
|
|
Active Comparator: Study group four
The precise selection of brand name depends on negotiations with suppliers and may change during the study period
|
Biomatrix drug eluting stent
Muut nimet:
|
|
Active Comparator: Study group five
The precise selection of brand name depends on negotiations with suppliers and may change during the study period
|
Biomatrix drug eluting stent
Muut nimet:
|
|
Active Comparator: Study group one
The precise selection of brand name depends on negotiations with suppliers and may change during the study period
|
Biomatrix drug eluting stent
Muut nimet:
|
Mitä tutkimuksessa mitataan?
Ensisijaiset tulostoimenpiteet
Tulosmittaus |
Toimenpiteen kuvaus |
Aikaikkuna |
|---|---|---|
|
MACE
Aikaikkuna: Five year
|
Major adverse cardiac events defined as a composite of cardiac death, acute myocardial infraction and target vessel revascularisation
|
Five year
|
|
Stent thromboses
Aikaikkuna: Five year
|
Definite, propable and possible
|
Five year
|
|
Treatment failure
Aikaikkuna: Five Years
|
A specifically developed Treatment Failure Classification
|
Five Years
|
Toissijaiset tulostoimenpiteet
Tulosmittaus |
Toimenpiteen kuvaus |
Aikaikkuna |
|---|---|---|
|
Death of any cause
Aikaikkuna: One and five years
|
Ongoing quality assurance
|
One and five years
|
|
Self reported health questionnaires on general health and cardiac specific symptoms.
Aikaikkuna: One and five years
|
One and five years
|
|
|
Cardiac death
Aikaikkuna: One and five years
|
One and five years
|
|
|
Myocardial infarction
Aikaikkuna: One and five years
|
One and five years
|
|
|
Target lesion revascularisation
Aikaikkuna: One and five years
|
One and five years
|
|
|
Target vessel revascularisation
Aikaikkuna: One and five years
|
One and five years
|
|
|
Stent thrombosis
Aikaikkuna: One and five years
|
One and five years
|
|
|
Treatment Failure
Aikaikkuna: One and five years
|
One and five years
|
Yhteistyökumppanit ja tutkijat
Sponsori
Tutkijat
- Päätutkija: Anders M Galløe, Md.Ph.D., Zealand University Hospital
- Opintojen puheenjohtaja: Steen Carstensen, MD, Zealand University Hospital
- Opintojen puheenjohtaja: Ole Havndrup, MD, Zealand University Hospital
- Opintojen puheenjohtaja: Lars Kjøller-Hansen, MD, Zealand University Hospital
- Opintojohtaja: Gunnar VH Jensen, MD, Zealand University Hospital
- Opintojohtaja: Jørgen Jeppesen, MD, Glostrup University Hospital, Copenhagen
Opintojen ennätyspäivät
Opi tärkeimmät päivämäärät
Opiskelun aloitus
Ensisijainen valmistuminen (Odotettu)
Opintojen valmistuminen (Odotettu)
Opintoihin ilmoittautumispäivät
Ensimmäinen lähetetty
Ensimmäinen toimitettu, joka täytti QC-kriteerit
Ensimmäinen Lähetetty (Arvio)
Tutkimustietojen päivitykset
Viimeisin päivitys julkaistu (Arvio)
Viimeisin lähetetty päivitys, joka täytti QC-kriteerit
Viimeksi vahvistettu
Lisää tietoa
Tähän tutkimukseen liittyvät termit
Avainsanat
Muita asiaankuuluvia MeSH-ehtoja
Muut tutkimustunnusnumerot
- COPERNICOS
Nämä tiedot haettiin suoraan verkkosivustolta clinicaltrials.gov ilman muutoksia. Jos sinulla on pyyntöjä muuttaa, poistaa tai päivittää tutkimustietojasi, ota yhteyttä register@clinicaltrials.gov. Heti kun muutos on otettu käyttöön osoitteessa clinicaltrials.gov, se päivitetään automaattisesti myös verkkosivustollemme .